Summit Therapeutics Provides Notice of Financial Results for the First Quarter Ended 30 April 2018
June 01 2018 - 6:00AM
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT) will announce its
financial results for the first quarter ended 30 April 2018 on 5
June 2018.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is currently conducting clinical programs focused
on the genetic disease, Duchenne muscular dystrophy, and the
infectious disease, Clostridium difficile infection. Further
information is available at www.summitplc.com and Summit can be
followed on Twitter (@summitplc).
For more information, please contact:
|
|
|
Summit |
|
|
Glyn Edwards
/ Richard Pye (UK office) |
Tel: |
44 (0)1235 443 951 |
Erik Ostrowski /
Michelle Avery (US office) |
|
+1 617 225 4455 |
|
|
|
Cairn Financial
Advisers LLP (Nominated Adviser) |
Tel: |
+44 (0)20 7213
0880 |
Liam Murray / Tony
Rawlinson |
|
|
|
|
|
N+1
Singer (Joint Broker) |
Tel: |
+44 (0)20 7496
3000 |
Aubrey Powell / Jen
Boorer |
|
|
|
|
|
Panmure
Gordon (Joint Broker) |
Tel: |
+44 (0)20 7886
2500 |
Freddy Crossley |
|
|
|
|
|
MacDougall
Biomedical Communications (US) |
Tel: |
+1 781 235 3060 |
Karen Sharma |
|
ksharma@macbiocom.com |
|
|
|
Consilium
Strategic Communications (UK) |
Tel: |
+44 (0)20 3709
5700 |
Mary-Jane Elliott /
Jessica Hodgson / |
|
summit@consilium-comms.com |
Lindsey Neville |
|
|
|
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024